Genmab A/S Files 6-K for Incorporation by Reference
Ticker: GNMSF · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, administrative, registration-statement
Related Tickers: GMAB
TL;DR
Genmab files a 6-K, mostly procedural, to update its S-8 filings. No new material info.
AI Summary
Genmab A/S filed a Form 6-K on September 26, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial information but serves to update or supplement previously filed documents.
Why It Matters
This filing indicates Genmab A/S is fulfilling its reporting obligations by incorporating this document into its S-8 registration statements, which are typically used for employee stock plans.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial results or material business updates.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-013041 (document_id) — Accession Number
- 20240926 (date) — Filing Date
- 333-232693, 333-253519, 333-262970 and 333-277273 (registration_statement_id) — S-8 File Numbers
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on September 26, 2024.
What does it mean for this report to be 'incorporated by reference'?
It means that the information contained in this 6-K filing is considered part of Genmab A/S's registration statements on Form S-8 from the date of filing, unless superseded by later documents.
What type of SEC filing is this Form 6-K?
This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Does this filing contain new financial results for Genmab A/S?
No, this filing is primarily for administrative purposes related to incorporation by reference into existing registration statements and does not appear to contain new financial results or material business updates.
Filing Stats: 226 words · 1 min read · ~1 pages · Grade level 14.8 · Accepted 2024-09-26 15:23:56
Filing Documents
- tmb-20240926x6k.htm (6-K) — 18KB
- tmb-20240926xex99d1.htm (EX-99.1) — 24KB
- tmb-20240926xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-013041.txt ( ) — 49KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: SEPTEMBER 26, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated September 26, 2024: Grant of Restricted Stock Units and Warrants to Employees in Genmab